SAW PALMETTO NATURES PROSTATE HEALER: WHO WON?
It was a close tie with both medicines showing advantages and disadvantages. Both SP and Proscar similarly decreased the total IPSS score. There was improvement noted in both groups within 6 weeks, and the improvement continued as the study went on. Other findings included:
Prostate sizeboth medicines reduced the size of the prostate gland, however, Proscar was more effective with a 16% reduction versus SP at only 7%.
Quality of lifemore than half of the patients in both groups felt their quality of life had improved after 6 weeks of treatment and 70% reported improvement by 26 weeks. Both treatment regimens were thus comparable.
Sexual functiononly one patient in each treatment group withdrew from the study because of sexual problems. However, patients on Proscar reported a slight deterioration in sexual function compared to those on SP. They had a higher incidence of decreased libido, impotence, and ejaculatory disorders.
Urinary flowthe ability to urinate rapidly improved in both groups with a slightly higher improvement on Proscar
Residual volumethe amount of urine left in the bladder increased by 8 ml with SP and decreased by 4 ml with Proscar.
Acute urinary retentionseven patients on SP and three patients on Proscar had to be hospitalized due to worsening of symptoms and the inability to urinate.
The researchers conclude, "The results of this double-blind randomized study demonstrate that 320 mg daily of Permixon and 5 mg of finasteride are equally effective in the management of BPH. Unpublished observations suggest that Permixon is as active as finasteride on medium-sized and small prostates, but is less inhibitory on very large prostates. This difference might be at the origin of the higher incidence of urinary retention we noted with Permixon in this study.
"In the treatment of men with mild or moderate symptoms of BPH, Permixon and finasteride are clinically equivalent. The long-term efficacy of finasteride has been established in placebo-controlled studies; that of Permixon needs to be confirmed."
A great amount of discussion between the presenting panel and experts in the audience was generated. Skeptics complained that the trial period of 26 weeks was not long enough to come to any firm conclusions. It is known that the placebo effect is quite high in the therapy of BPH. Dr. Denis concludes, as practically every scientist does when asked what to make of the results of a study, "We hope to see more randomized trials in the near future confirming or refuting the data obtained in this trial."
*24\299\2*
Men's Health Erectile Dysfunction